Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trilostane

Drug Profile

Trilostane

Alternative Names: Abetafen; Modrastane; Modrefen; Modrenal

Latest Information Update: 14 Dec 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stegram Pharmaceuticals
  • Class Androstanols; Testosterone congeners
  • Mechanism of Action 3-hydroxysteroid dehydrogenase inhibitors; Estrogen receptor antagonists; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • No development reported Adrenal cortical hyperfunction; Prostate cancer
  • Discontinued Alzheimer's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 08 Sep 2009 No development reported - Clinical for Breast cancer in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top